SNS Financial Group’s Gilead Sciences GILD Stock Holding History

SNS Financial Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,500	Closed	-$102K	–	182
2017 Q1	$102K	Buy	+1,500	New	+$105K	0.03%	178

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SNS Financial Group's GILD Position: Q1 2023 in Review

SNS Financial Group sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 4,126 shares — an estimated $354K sold.

SNS Financial Group first reported a position in GILD in Q2 2015 and held it in 29 quarters. The position peaked at $4.37M in Q4 2015. 1,736 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

SNS Financial Group reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
SNS Financial Group sold 4,126 Gilead Sciences shares in Q1 2023, an estimated $354K.
SNS Financial Group first reported a position in Gilead Sciences in Q2 2015 and held it in 29 quarters.
SNS Financial Group's Gilead Sciences position peaked at $4.37M in Q4 2015.
1,736 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on SNS Financial Group's 13F filing for Q1 2023, filed 28 Apr 2023.